Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Computerized Thermal Imaging CIO (formerly COII) -- Ignore unavailable to you. Want to Upgrade?

To: pilapir who wrote (5995)	11/15/2001 6:33:11 PM
From: Profiteer	Respond to of 6039

CTI Unveils Interactive Demonstration!! CTI Unveils Interactive Demonstration of Breast Imaging System at Major Medical Meeting PORTLAND, Ore., Nov 15, 2001 /PRNewswire via COMTEX/ -- For the first time outside of clinical trials, Computerized Thermal Imaging Inc. (CTI) (AMEX: CIO) is giving radiologists a chance to try out its new breast imaging system, the CTI Breast Cancer System 2100(TM), at the annual meeting of the Radiological Society of North America (RSNA). The RSNA trade show opens Nov. 25 and runs through Nov. 29 at McCormick Place in Chicago. Using patient cases from CTI's clinical trials, radiologists from around the world will be able to review a mammogram and the corresponding thermal image taken by the CTI breast imaging system. The radiologist will be able to use the CTI breast imaging system analysis software to assist in determining whether there is a malignancy. After a diagnosis is made, radiologists will be able to compare their diagnosis with the pathology report of each case. "By allowing radiologists to use the system as it will be used in a hospital setting, they can experience firsthand the advantages of having a second view of the breast tissue," said John M. Brenna, company president and COO. "Our breast imaging system provides a physiological view of the tissue that complements the anatomical view provided by mammography." CTI is awaiting approval from the U.S. Food and Drug Administration (FDA) for its breast imaging system to be used in addition to mammograms and physician examinations in the detection of breast cancer. CTI submitted the final module of its Pre-Market Approval (PMA) application to the FDA in June 2001. The final module contained data from CTI's clinical studies. The study data show promising results in several areas, particularly with the system's ability to predict benign conditions, its overall adjunctive value when used with mammography, as well as the system's performance in specific categories of patients such as those with dense breast tissue, which can be difficult to diagnose with mammography alone. The FDA has already accepted four of the five modules CTI submitted for its breast imaging system. The CTI breast imaging system uses thermal imaging to help doctors differentiate between benign and malignant breast lesions. It is painless, non-invasive, and requires no patient exposure to radiation, breast compression, or electrical current. The CTI breast imaging system detects heat given off by the breast, creates a digital image of that heat pattern, and instantly displays a composite thermal image for each area of the breast. The CTI breast imaging system will not replace the need for a mammogram. Instead, pending FDA approval, it may be used following an abnormal mammogram to provide additional information that may assist physicians in determining more precisely when a surgical biopsy is needed. The Breast Cancer System 2100 is presently available in the U.S. only as an investigational device and is not available for sale until approved by the FDA. Computerized Thermal Imaging Inc. is in business to improve the quality of life through the development and deployment of thermal imaging and associated technologies. Information about CTI can be found on the Internet at www.cti-net.com or by calling CTI Public Affairs at (503) 594-1210. Except for historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In addition to the factors set forth above, other important factors that could cause actual results to differ materially include, but are not limited to, technical risks associated with new technology development, government regulatory approvals and access to working capital. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings. Copies of these filings may be obtained by contacting the Company or the SEC. The Company undertakes no obligation to update any of the forward-looking statements contained in its press releases.